New hope for diabetes control after kidney transplant?
NCT ID NCT00466518
First seen Apr 14, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study looked at how the diabetes drug sitagliptin affects levels of anti-rejection medicines (tacrolimus and sirolimus) in people who had a kidney transplant and also have type 2 diabetes. Sixteen participants were monitored for changes in drug levels, blood sugar control, and side effects over three months. The goal was to find a safe way to manage diabetes without interfering with transplant medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198-1230, United States
Conditions
Explore the condition pages connected to this study.